CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
It was a negative week for stock markets as the S&P/ASX 200 (INDEXASX:XJO) dropped 0.5%. Here are my three key ASX takeaways.
The S&P/ASX 200 (ASX: XJO) bucked the trend to gain 0.2% on Friday as Novonix (ASX:NVX) and CSL (AS:CSL) shares were in the news.
The CSL Limited (ASX:CSL) share price is in focus on reports that it could be about to make a multi-billion acquisition of Vifor Pharma.
Washington H. Soul Pattinson (ASX: SOL) is almost a dividend aristocrat and has increased its dividend for 21 years – the longest consecutive streak of the ASX.
There are quite a few ASX shares that I prefer compared to Vanguard Australian Shares Index ETF (ASX:VAS).
Share buybacks are often-overlooked by management, though can turbocharge your dividend growth investing if properly executed.
The S&P/ASX 200 (ASX: XJO) experienced a rare loss on Monday as SiteMinder (ASX:SDR) and Sydney Airport (ASX:SYD) shares made headlines.
The three keys to long term value creation are no hidden secret: profit growth, changes in valuation multiples, and cash flow contributions.
The S&P/ASX 200 (ASX:XJO) managed to eke out another small gain on Wednesday as Woolies (ASX:WOW) and a2 Mik (ASX:A2M) shares made headlines.
